Shares of EDGE MEDICAL-B (02675) climbed more than 8% on Thursday, trading up 8.1% to HK$36.58 at the time of writing, with turnover reaching HK$23.81 million.

According to the company's interim results for 2026, revenue for the first half of the year reached RMB 319 million, representing a year-on-year increase of 113.8%, primarily attributed to the rapid growth of surgical robot sales in both domestic and international markets. Notably, revenue from products sold to overseas end-users amounted to RMB 222 million, accounting for approximately 69.8% of total revenue. The loss attributable to equity shareholders narrowed by 78.4% year-on-year to RMB 19.25 million.

As of the end of the first half, the company had installed or delivered a total of 158 surgical robots globally, with 55 units delivered to end-users in China and 103 units to overseas markets.

Where to begin with this growth story: EDGE MEDICAL stands out as a leading domestic manufacturer of endoscopic surgical robots, having built a comprehensive product matrix. The company's revenue compound annual growth rate (CAGR) exceeded 200% between 2023 and 2025, signaling an explosive growth phase. International commercialization commenced in 2025, with product sales to overseas end-users generating RMB 272 million in revenue that year, representing more than 50% of total revenue. With gross margins steadily improving and expense ratios compressing, the company's profitability outlook is strengthening, positioning it on track to achieve a turnaround to profitability.